Is GlaxoSmithKline plc a better dividend buy than Standard Life plc and Legal & General Group plc?

Does a lack of dividend growth hold back GlaxoSmithKline plc’s (LON: GSK) income appeal versus Standard Life plc (LON: SL) and Legal & General Group plc (LON: LGEN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While GlaxoSmithKline (LSE: GSK) has a relatively high yield of 5.5%, one concern among investors is its lack of forecast dividend growth. In fact, the health care company is expected to keep dividends at their current level over the next couple of financial years as it seeks to reinvest for future growth and to also increase its dividend coverage ratio.

Both of these uses of cash seem to be perfectly sound and should help to improve the company’s long-term profit growth prospects. However, it means that GlaxoSmithKline’s investors are unlikely to see their income growth beat inflation and if inflation spikes then this could be a worry.

However, beyond the next couple of years, GlaxoSmithKline looks set to grow shareholder payouts at a rapid rate. That’s at least partly because it has an excellent pipeline of new drugs, with around 40 treatments having the potential to improve the company’s bottom line. And with its consumer goods segment offering stability, GlaxoSmithKline seems to offer the perfect mix of dividend growth potential, stability and a high yield.

Fast dividend growth?

Of course, it’s not the only company with excellent income prospects. Diversified financial services companies Standard Life (LSE: SL) and Legal & General (LSE: LGEN) both have excellent yields and could grow dividends at a faster rate than even GlaxoSmithKline in the long run.

For example, Standard Life currently yields 5.9% and with dividends forecast to rise by over 7% next year, it could become increasingly popular among income-seeking investors. Furthermore, with dividends being covered 1.35 times by profit, there seems to be sufficient headroom to increase dividends at a faster rate than profit over the coming years. And with Standard Life forecast to grow its bottom line by 10% next year, there’s the potential for a double-digit increase in dividends over the medium term.

Similarly, Legal & General offers a high yield and upbeat dividend growth prospects. It currently yields 6.1% and with dividends being covered 1.4 times by profit, there’s scope for a rapid rise in shareholder payouts in future. Plus, with Legal & General having increased dividends per share by 120% over the last five years, it has an excellent track record when it comes to rewarding shareholders with higher dividends.

Glaxo resilience

However, while Standard Life and Legal & General are top-notch income stocks, GlaxoSmithKline appears to be more appealing. That’s because it has lower positive correlation with the wider economy than is the case for its index peers and this means that dividends are unlikely to come under the same degree of pressure in an economic downturn. In other words, dividends at GlaxoSmithKline may be more resilient in an uncertain economic climate. As such, it seems to be the pick of the three stocks from an income-seeking perspective.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline, Legal & General Group, and Standard Life. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the S&P 500 be heading for an almighty crash?

Christopher Ruane shares his take on why he thinks the S&P 500 could be heading for a big fall at…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Down 64%, this FTSE 250 stock offers a 13% dividend yield for investors

This struggling investment banker has suffered significant losses in the past five years, but it has the second-highest yield on…

Read more »

Investing Articles

1 stock market ETF I’ve been buying during the sell-off

The stock market's been all over the place in April, creating a fertile breeding ground for long-term buying opportunities.

Read more »

Investing Articles

As the Sainsbury share price bucks the price-war trend on FY results, I examine the dividend prospects

The J Sainsbury share price has been regaining ground, despite growing fears of intense competition in the supermarket sector.

Read more »

The words "what's your plan for retirement" written on chalkboard on pavement somewhere in London
Investing Articles

Should I invest in a Stocks and Shares ISA or a SIPP to retire early?

Early retirement is the ultimate goal for many investors, but choosing between a Stocks and Shares ISA and a pension…

Read more »

Investing Articles

Is now a great time to consider buying Greggs shares?

Greggs shares have been hammered in 2025. But have they now fallen too far? Paul Summers takes another look at…

Read more »

Investing Articles

Is it still a great time to buy cheap shares as stock market crash fears recede?

Fear of a stock market crash can trigger panic selling... but that surely can't be the best thing to do…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

The Vodafone share price is 24% undervalued, according to analysts

Our writer’s been looking at the latest targets for the Vodafone share price. Although there’s a wide variation, the average…

Read more »